Compare AbbVie Inc (ABBV) vs Jumia Technologies AG - ADR (JMIA) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

JMIA trades at $6.94, down 1.56% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth of 39% year-over-year, narrowing its adjusted EBITDA loss by 32%. Analyst consensus is strongly bullish with 71% buy ratings, supported by management's reaffirmed path to profitability by 2027. Cash flow improved in 2025 with a net inflow of $21.31 million, though the company remains unprofitable with a net income margin of -30.79%.

The outlook hinges on JMIA's execution toward its 2027 profitability target, with upside from African e-commerce expansion and partnerships like Starlink. Key risks include persistent losses, competitive pressures, and macroeconomic volatility in operating regions. Investors should weigh the growth potential against the high valuation multiples and financial sustainability concerns.